Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations
Dominik Rottenkolber(Helmholtz Zentrum München), Joerg Hasford(German Medical Association), Silke Mueller(University of Rostock), Katrin Farker(Jena University Hospital), Marietta Rottenkolber(Zimmer Biomet (Germany)), Marion Hippius, Karen Saljé(Universität Greifswald), Petra Thuermann(Helios Universitätsklinikum Wuppertal), Sven Schmiedl(Witten/Herdecke University)
Cited by 169
Related Papers
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573